Dual targeting of PD-1/PD-L1 and iL-33/ST2 signalling pathways: a promising approach in breast cancer immunotherapy
Introduction The immune checkpoint axis PD-1/PD-L1 is a cornerstone of cancer immunotherapy. However, its efficacy in breast cancer is often limited by a complex and immunosuppressive tumour microenvironment (TME). The IL-33/ST2 signalling pathway, a key player in type 2 inflammation, is increasingl...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Taylor & Francis Group
2025-12-01
|
| Seri Bilgileri: | Annals of Medicine |
| Konular: | |
| Online Erişim: | https://www.tandfonline.com/doi/10.1080/07853890.2025.2593198 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|